On this week’s show, a trip to the Middle proves successful for MaRS Innovation, a Boston jury rules against BC med tech company Neovasc, Genetically modified Salmon get the green light in Canada, and researchers uncover why the drug cetuximab works in some patients with colorectal cancer and not others.